TWI238064B
(en)
|
1995-06-20 |
2005-08-21 |
Takeda Chemical Industries Ltd |
A pharmaceutical composition for prophylaxis and treatment of diabetes
|
US6291495B1
(en)
*
|
1997-02-24 |
2001-09-18 |
Robert B. Rieveley |
Method and composition for the treatment of diabetes
|
AU6452098A
(en)
|
1997-03-07 |
1998-09-22 |
Metabasis Therapeutics, Inc. |
Novel purine inhibitors of fructose-1,6-bisphosphatase
|
US6099859A
(en)
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
US6099862A
(en)
*
|
1998-08-31 |
2000-08-08 |
Andrx Corporation |
Oral dosage form for the controlled release of a biguanide and sulfonylurea
|
CA2343027A1
(en)
|
1998-09-09 |
2000-03-16 |
Metabasis Therapeutics, Inc. |
Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
|
US20040102486A1
(en)
*
|
1998-11-12 |
2004-05-27 |
Smithkline Beecham Corporation |
Novel method of treatment
|
GB9824893D0
(en)
*
|
1998-11-12 |
1999-01-06 |
Smithkline Beckman Corp |
Novel method of treatment
|
US20030153607A1
(en)
*
|
1998-11-12 |
2003-08-14 |
Smithkline Beecham P.L.C. |
Novel composition and use
|
US20040081697A1
(en)
*
|
1998-11-12 |
2004-04-29 |
Smithkline Beecham P.L.C. |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
US6878749B2
(en)
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
US6586438B2
(en)
*
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
ATE350385T1
(de)
|
2000-03-08 |
2007-01-15 |
Metabasis Therapeutics Inc |
Neue aryl fructose-1,6-bisphosphatase inhibitoren
|
US6296874B1
(en)
*
|
2000-05-01 |
2001-10-02 |
Aeropharm Technology Incorporated |
Core formulation comprising troglitazone and abiguanide
|
US6780432B1
(en)
*
|
2000-05-01 |
2004-08-24 |
Aeropharm Technology, Inc. |
Core formulation
|
US6610272B1
(en)
|
2000-05-01 |
2003-08-26 |
Aeropharm Technology Incorporated |
Medicinal aerosol formulation
|
CA2407713A1
(en)
*
|
2000-05-01 |
2001-11-08 |
Aeropharm Technology, Inc. |
A core formulation
|
KR100713234B1
(ko)
*
|
2000-10-02 |
2007-05-02 |
유에스브이 리미티드 |
메트포민을 함유하는 지속방출형 약학 조성물 및 이의제조방법
|
US6866866B1
(en)
*
|
2000-11-03 |
2005-03-15 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
EP1738751B1
(en)
|
2001-01-12 |
2011-05-11 |
Sun Pharma Advanced Research Company Ltd |
Spaced drug delivery system
|
KR200249057Y1
(ko)
*
|
2001-03-22 |
2001-10-19 |
김진환 |
뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
|
FR2823225B1
(fr)
*
|
2001-04-04 |
2004-09-17 |
Pierre Desreumaux |
Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant
|
EP1377276B1
(en)
*
|
2001-04-10 |
2011-10-05 |
Sun Pharma Advanced Research Company Limited |
Timed pulse release composition
|
US20040156903A1
(en)
*
|
2002-05-22 |
2004-08-12 |
Abrams Andrew L.. |
Metering and packaging of controlled release medication
|
SE0101980D0
(sv)
*
|
2001-06-01 |
2001-06-01 |
Astrazeneca Ab |
Pharmaceutical combination
|
SE0101982D0
(sv)
*
|
2001-06-01 |
2001-06-01 |
Astrazeneca Ab |
Pharmaceutical combination
|
WO2003005991A1
(en)
*
|
2001-07-10 |
2003-01-23 |
Aeropharm Technology Incorporated |
A core formulation
|
EP1429747A4
(en)
*
|
2001-07-10 |
2005-01-05 |
Kos Life Sciences Inc |
CORE FORMULATION WITH PIOGLITAZONE HYDROCHLORIDE AND A BIGUANIDE
|
MXPA04000181A
(es)
*
|
2001-07-10 |
2004-11-22 |
Kos Life Sciences Inc |
Formulacion de nucleo que comprende troglitazona y una biguanida.
|
MXPA04000324A
(es)
*
|
2001-07-17 |
2004-07-23 |
N Gene Res Lab Inc |
Una combinacion farmaceutica sinergistica para la prevencion o tratamiento de diabetes.
|
JP4965060B2
(ja)
*
|
2001-07-27 |
2012-07-04 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
バウヒニア抽出物
|
JP4353414B2
(ja)
*
|
2001-07-30 |
2009-10-28 |
田辺三菱製薬株式会社 |
食後過血糖改善剤
|
FR2832633B1
(fr)
*
|
2001-11-28 |
2004-09-24 |
Lipha |
Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
|
US7183321B2
(en)
*
|
2001-12-17 |
2007-02-27 |
Bristol-Myers Squibb Company |
Antidiabetic formulation and method
|
FR2834640B1
(fr)
*
|
2002-01-11 |
2004-09-24 |
Lipha |
Composition pharmaceutique comprenant une glitazone et un acide 4-oxobutanoique et son utilisation pour traiter le diabete
|
WO2003061643A1
(es)
*
|
2002-01-25 |
2003-07-31 |
Laboratorios Silanes, S.A. De C.V. |
Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
US20030187074A1
(en)
*
|
2002-03-04 |
2003-10-02 |
Javed Hussain |
Oral compositions for treatment of diabetes
|
US8911781B2
(en)
|
2002-06-17 |
2014-12-16 |
Inventia Healthcare Private Limited |
Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
|
US8821915B2
(en)
|
2002-08-09 |
2014-09-02 |
Veroscience, Llc |
Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
|
US20040081678A1
(en)
*
|
2002-08-09 |
2004-04-29 |
Anthony Cincotta |
Therapeutic process for the treatment of obesity and associated metabolic disorders
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US9060941B2
(en)
*
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7959946B2
(en)
*
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US8084058B2
(en)
|
2002-09-20 |
2011-12-27 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7785627B2
(en)
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
AU2003272504A1
(en)
|
2002-09-20 |
2004-04-08 |
Andrx Labs Llc |
Multistage formulation containing a biguanide and thiazolidindione derivatives
|
MXPA05003252A
(es)
*
|
2002-09-26 |
2005-07-05 |
Eisai Co Ltd |
Farmaco de combinacion.
|
IN192749B
(es)
*
|
2002-11-15 |
2004-05-15 |
Ranbaxy Lab Ltd |
|
WO2004108067A2
(en)
*
|
2003-04-03 |
2004-12-16 |
Sun Pharmaceutical Industries Limited |
Programmed drug delivery system
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
WO2005009412A1
(en)
*
|
2003-07-24 |
2005-02-03 |
Wockhardt Limited |
Oral compositions for treatment of diseases
|
US20050054731A1
(en)
*
|
2003-09-08 |
2005-03-10 |
Franco Folli |
Multi-system therapy for diabetes, the metabolic syndrome and obesity
|
DK1677792T3
(en)
|
2003-10-31 |
2015-12-14 |
Takeda Pharmaceutical |
FIXED COMPOSITION INCLUDING PIOGLITAZONE, GLIME PIRIDE AND A POLYOXYETHYLENE-SORBITAN Fatty Acid Ester.
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
EP1807066A1
(en)
*
|
2004-10-25 |
2007-07-18 |
Novartis AG |
Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
WO2006074278A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Mitsunori Ono |
Compositions for treating diabetes or obesity
|
US20070015839A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Franco Folli |
Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
|
MXPA05009633A
(es)
*
|
2005-09-08 |
2007-03-07 |
Silanes Sa De Cv Lab |
Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
|
MXPA05010977A
(es)
*
|
2005-10-12 |
2007-04-11 |
Abdala Leopoldo Espinosa |
Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus.
|
MXPA05014092A
(es)
*
|
2005-12-20 |
2007-06-20 |
Leopoldo De Jesus Espinosa Abdala |
Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.
|
FR2896159B1
(fr)
*
|
2006-01-13 |
2008-09-12 |
Merck Sante Soc Par Actions Si |
Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
|
US20070249561A1
(en)
*
|
2006-04-25 |
2007-10-25 |
Taylor Bradley K |
Pharmacological method for treatment of neuropathic pain
|
PE20080251A1
(es)
*
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
NO347644B1
(no)
|
2006-05-04 |
2024-02-12 |
Boehringer Ingelheim Int |
Polymorfer
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
US20090238763A1
(en)
|
2006-07-09 |
2009-09-24 |
Chongxi Yu |
High penetration compositions and uses thereof
|
US20090221703A1
(en)
|
2006-07-09 |
2009-09-03 |
Chongxi Yu |
High penetration composition and uses thereof
|
TW200816995A
(en)
*
|
2006-08-31 |
2008-04-16 |
Daiichi Sankyo Co Ltd |
Pharmaceutical composition containing insulin sensitizers
|
PL2084124T3
(pl)
|
2006-10-02 |
2014-08-29 |
Techfields Biochem Co Ltd |
Dodatnio naładowane rozpuszczalne w wodzie proleki prostaglandyn i związków pokrewnych o bardzo dużych szybkościach przenikania przez skórę
|
CN101541743A
(zh)
|
2006-11-08 |
2009-09-23 |
于崇曦 |
多肽及相关化合物的透皮给药系统
|
JP5324463B2
(ja)
|
2006-12-10 |
2013-10-23 |
チョンシー ユー |
β−ラクタム抗生物質の経皮送達システム
|
JP5826459B2
(ja)
|
2007-01-15 |
2015-12-02 |
チョンシー ユー |
非常に高い皮膚浸透率を有するレチノイド及びレチノイド様化合物の正に荷電した水溶性プロドラッグ
|
EP2115140B8
(en)
|
2007-01-31 |
2017-01-25 |
Chongxi Yu |
Positively charged water-soluble prodrugs of 1H-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
US8426439B2
(en)
*
|
2007-04-11 |
2013-04-23 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
US20160331729A9
(en)
|
2007-04-11 |
2016-11-17 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
US11241420B2
(en)
|
2007-04-11 |
2022-02-08 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
CN101687792B
(zh)
|
2007-06-04 |
2016-03-02 |
于崇曦 |
具有快速皮肤和生物膜穿透速度的非甾体抗炎药的前药及其医药用途
|
US20110112069A1
(en)
*
|
2007-08-17 |
2011-05-12 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
WO2010011860A1
(en)
*
|
2008-07-23 |
2010-01-28 |
Diabetomics, Llc |
Methods for detecting pre-diabetes and diabetes
|
UY32030A
(es)
*
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
WO2010018217A2
(en)
*
|
2008-08-15 |
2010-02-18 |
Boehringer Ingelheim International Gmbh |
Organic compounds for wound healing
|
US20110144055A1
(en)
*
|
2008-09-04 |
2011-06-16 |
Rozmanith Anthony I |
Health Care
|
US20100075937A1
(en)
*
|
2008-09-24 |
2010-03-25 |
Hollis-Eden Pharmaceuticals, Inc. |
Patient populations and treatment methods
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
CN108191846B
(zh)
*
|
2008-12-04 |
2021-08-20 |
于崇曦 |
高穿透性组合物及其应用
|
MX2011006713A
(es)
|
2008-12-23 |
2011-07-13 |
Boehringer Ingelheim Int |
Formas salinas de compuesto organico.
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
WO2010105103A1
(en)
|
2009-03-11 |
2010-09-16 |
Omeros Corporation |
Compositions and methods for prophylaxis and treatment of addictions
|
CN104856985B
(zh)
|
2009-04-29 |
2019-01-04 |
阿马里纳制药爱尔兰有限公司 |
稳定的药物组合物和使用其的方法
|
CN104042617A
(zh)
|
2009-04-29 |
2014-09-17 |
阿马里纳药物爱尔兰有限公司 |
含有epa和心血管剂的药物组合物以及使用其的方法
|
AU2010244857A1
(en)
|
2009-05-08 |
2011-11-10 |
Techfields Biochem Co., Ltd. |
High penetration prodrug compositions of peptides and peptide-related compounds
|
US9352025B2
(en)
|
2009-06-05 |
2016-05-31 |
Veroscience Llc |
Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
|
US9969751B2
(en)
|
2009-06-10 |
2018-05-15 |
Techfields Pharma Co., Ltd. |
High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
|
KR20120016677A
(ko)
|
2009-06-15 |
2012-02-24 |
아마린 파마, 인크. |
병용 스타틴 요법을 받는 대상체에서 ldl-c 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
|
US20110065756A1
(en)
*
|
2009-09-17 |
2011-03-17 |
De Taeye Bart M |
Methods and compositions for treatment of obesity-related diseases
|
EA034869B1
(ru)
|
2009-11-27 |
2020-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
|
WO2011128782A2
(en)
*
|
2010-04-13 |
2011-10-20 |
Jorge Luis Rosado |
Compositions and methods for treating type ii diabetes and related disorders
|
MX341025B
(es)
|
2010-05-05 |
2016-08-04 |
Boehringer Ingelheim Int Gmbh * |
Terapia de combinacion.
|
US9241952B2
(en)
|
2010-05-24 |
2016-01-26 |
Ozstar Therapeutics Pty Ltd |
Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin
|
BR112012032579B1
(pt)
|
2010-06-24 |
2021-05-11 |
Boehringer Ingelheim International Gmbh |
uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
NZ611606A
(en)
|
2010-11-29 |
2015-10-30 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
KR101985384B1
(ko)
|
2011-07-15 |
2019-06-03 |
베링거 인겔하임 인터내셔날 게엠베하 |
치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
CN103159651B
(zh)
*
|
2011-12-14 |
2015-06-17 |
安徽贝克联合制药有限公司 |
磺酰脲胍及其制备方法和用途
|
EP4356912A2
(en)
|
2012-01-18 |
2024-04-24 |
Techfields Pharma Co., Ltd. |
High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
NL2015957B1
(en)
|
2015-12-14 |
2017-06-29 |
Scala Pharma B V |
Compositions and methods for inducing beige or brown fat tissue.
|
EP3184106A1
(en)
|
2015-12-23 |
2017-06-28 |
Sanofi-Aventis Deutschland GmbH |
Growth differentiation factor 15 as biomarker for metformin
|
CN109310697A
(zh)
|
2016-06-10 |
2019-02-05 |
勃林格殷格翰国际有限公司 |
利格列汀和二甲双胍的组合
|
MA51765A
(fr)
|
2018-09-24 |
2020-12-16 |
Amarin Pharmaceuticals Ie Ltd |
Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
|
NL2024493B1
(en)
|
2019-12-16 |
2021-09-02 |
Logick Energetics B V |
Pharmaceutical composition for preventing or stopping metastases
|
WO2021125951A1
(en)
|
2019-12-18 |
2021-06-24 |
Logick Energetics B.V. |
Pharmaceutical composition for use in preventing or stopping metastases
|
NL2025335B1
(en)
|
2020-04-10 |
2021-10-26 |
Logick Energetics B V |
Pharmaceutical composition for treatment of corona virus infection
|
KR20240012390A
(ko)
|
2021-04-21 |
2024-01-29 |
애머린 파마슈티칼스 아일랜드 리미티드 |
심부전의 위험을 감소시키는 방법
|
NL2028476B1
(en)
|
2021-06-17 |
2022-12-27 |
Logick Energetics B V |
Pharmaceutical composition for increasing mitochondrial activity and/or improving adiponectin production
|
NL2029634B1
(en)
|
2021-11-04 |
2023-06-02 |
Logick Energetics B V |
Pharmaceutical composition for increasing mitochondrial activity and/or improving adiponectin production
|